Atrys Health (XMAD:ATRY) Return-on-Tangible-Equity: 0.00% (As of Dec. 2025)


XMAD:ATRY Atrys Health SA XMAD:ATRY
66 GF Score
Price €2.53
GF Value €3.12
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Atrys Health Return-on-Tangible-Equity?

Atrys Health XMAD:ATRY -0.20% 66 Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus rates XMAD:ATRY with a GF Score™ of 66/100 and a GF Value™ of €3.12 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 1,200 Biotechnology companies, Atrys Health ranks worse than 83333.25% on this metric.

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Atrys Health's annualized net income for the quarter that ended in Dec. 2025 was €-182.0 Mil. Atrys Health's average shareholder tangible equity for the quarter that ended in Dec. 2025 was €-115.0 Mil. Therefore, Atrys Health's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 was N/A%.

The historical rank and industry rank for Atrys Health's Return-on-Tangible-Equity or its related term are showing as below:

During the past 10 years, Atrys Health's highest Return-on-Tangible-Equity was 2.04%. The lowest was 0.00%. And the median was 2.04%.

XMAD:ATRY's Return-on-Tangible-Equity is not ranked *
in the Biotechnology industry.
Industry Median: -42.435
* Ranked among companies with meaningful Return-on-Tangible-Equity only.

Atrys Health  (XMAD:ATRY) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Atrys Health Return-on-Tangible-Equity Related Terms


Atrys Health Return-on-Tangible-Equity Historical Data

* Premium members only.

The historical data trend for Atrys Health's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Atrys Health Return-on-Tangible-Equity Chart

Atrys Health Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Return-on-Tangible-Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Atrys Health Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

XMAD:ATRY vs VRTX, REGN, ALNY: Return-on-Tangible-Equity Comparison

For the Biotechnology subindustry, Atrys Health's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Atrys Health Return-on-Tangible-Equity vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Atrys Health's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Atrys Health's Return-on-Tangible-Equity falls into.


XMAD:ATRY
66GF Score
Atrys Health SA XMAD:ATRY
Return-on-Tangible-Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Atrys Health Return-on-Tangible-Equity Calculation

Atrys Health's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-100.296/( (-170.993+-56.214 )/ 2 )
=-100.296/-113.6035
=N/A %

Atrys Health's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2025 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-182.012/( (-173.873+-56.214)/ 2 )
=-182.012/-115.0435
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2025) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.

What does a Return-on-Tangible-Equity of 0.00% mean?
Atrys Health (XMAD:ATRY) has a Return-on-Tangible-Equity of 0.00% as of Dec. 2025. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Atrys Health and its competitors. According to the industry distribution chart, Atrys Health ranks #999999 out of 1200 companies in the Biotechnology industry.
Is Atrys Health's Return-on-Tangible-Equity too high?
Atrys Health's current Return-on-Tangible-Equity is 0.00%. Based on the distribution chart, Atrys Health ranks #999999 out of 1200 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Atrys Health has a GF Score™ of 66/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Atrys Health's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Atrys Health ranks #999999 out of 1200 companies for Return-on-Tangible-Equity. This places Atrys Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Atrys Health and its competitors. Atrys Health's current Return-on-Tangible-Equity is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atrys Health stock overvalued right now?
Based on GuruFocus' analysis, Atrys Health (XMAD:ATRY) is currently considered Modestly Undervalued. The stock's GF Value™ is €3.12, compared to a current price of €2.53 — trading 18.9% below its estimated fair value. The current Return-on-Tangible-Equity is 0.00%. Atrys Health's overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Atrys Health (XMAD:ATRY), the current Return-on-Tangible-Equity is 0.00% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Atrys Health (XMAD:ATRY) Overvalued in 2026?

Based on GuruFocus' analysis, Atrys Health stock appears to be undervalued. The current stock price of €2.53 is trading 18.9% below its estimated GF Value™ of €3.12. GuruFocus considers Atrys Health to be Modestly Undervalued.

Key valuation signals for XMAD:ATRY:

  • Return-on-Tangible-Equity: 0.00%
  • GF Value™: €3.12 vs. price of €2.53 (18.9% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the XMAD:ATRY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Atrys Health Business Description

Other Exchanges A2T:Germany
Address Calle Provenca, 392 planta baja, Barcelona, ESP, 08025
Atrys Health SA is a Spain based biomedical company which focuses on developing tools for the diagnosis and treatment of cancer and precancerous conditions. It offers diagnostic services in the fields of pathology, hematology, molecular pathology, and genetics. The company uses telemedicine to provide its services in the medical specialties of radiology, cardiology, ophthalmology, and dermatology.
66GF Score

Get the complete analysis for XMAD:ATRY

Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.53
Price
€3.12
GF Value